Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Mattingly, Gregory W
Wilson, Joshua
and
Rostain, Anthony L
2017.
A clinician’s guide to ADHD treatment options.
Postgraduate Medicine,
Vol. 129,
Issue. 7,
p.
657.
Via, Kamala D.
2019.
Preventing the Next Epidemic: Prescribed Stimulant Abuse.
The Journal for Nurse Practitioners,
Vol. 15,
Issue. 3,
p.
232.
Mattingly, Gregory W.
and
Young, Joel
2021.
A clinician’s guide for navigating the world of attention deficit hyperactivity disorder medications.
CNS Spectrums,
Vol. 26,
Issue. 2,
p.
104.
Nasser, Azmi
Hull, Joseph T
Liranso, Tesfaye
Busse, Gregory D
Melyan, Zare
Childress, Ann C
Lopez, Frank A
and
Rubin, Jonathan
2021.
The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials.
Neuropsychiatric Disease and Treatment,
Vol. Volume 17,
Issue. ,
p.
1751.
Cambron-Mellott, M Janelle
Mikl, Jaromir
Matos, Joana E
Erensen, Jennifer G
Beusterien, Kathleen
Cataldo, Marc J
Hallissey, Bernadette
and
Mattingly, Gregory W
2021.
Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment.
Patient Preference and Adherence,
Vol. Volume 15,
Issue. ,
p.
1061.
Nasser, Azmi
Liranso, Tesfaye
Adewole, Toyin
Fry, Nicholas
Hull, Joseph T.
Busse, Gregory D.
Chowdhry, Fatima
Cutler, Andrew J.
Jones, Nandita Joshi
Findling, Robert L.
and
Schwabe, Stefan
2021.
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Journal of Clinical Psychopharmacology,
Vol. 41,
Issue. 4,
p.
370.
Nasser, Azmi
Liranso, Tesfaye
Adewole, Toyin
Fry, Nicholas
Hull, Joseph T.
Chowdhry, Fatima
Busse, Gregory D.
Melyan, Zare
Cutler, Andrew J.
Findling, Robert L.
and
Schwabe, Stefan
2021.
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial.
Clinical Therapeutics,
Vol. 43,
Issue. 4,
p.
684.
Cutler, Andrew J.
Mattingly, Gregory W.
Jain, Rakesh
and
O’Neal, Welton
2022.
Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents.
CNS Spectrums,
Vol. 27,
Issue. 2,
p.
199.
Mechler, Konstantin
Banaschewski, Tobias
Hohmann, Sarah
and
Häge, Alexander
2022.
Evidence-based pharmacological treatment options for ADHD in children and adolescents.
Pharmacology & Therapeutics,
Vol. 230,
Issue. ,
p.
107940.
Gomez, Renato Santiago
and
Fernandes, Magda Lourenço
2022.
Treatments, Mechanisms, and Adverse Reactions of Anesthetics and Analgesics.
p.
81.